Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study

Abstract Background Triple therapy is recommended for patients with chronic obstructive pulmonary disease (COPD) who remain symptomatic despite dual therapy. The optimal timing of triple therapy following an exacerbation of COPD is unknown. The outcomes of prompt (≤ 30 days) vs. delayed (31–180 days...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Afisi S. Ismaila, Kieran J. Rothnie, Robert P. Wood, Victoria L. Banks, Lucinda J. Camidge, Alexandrosz Czira, Chris Compton, Raj Sharma, Shannon N. Millard, Olivia Massey, David M. G. Halpin
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	BMC 2023-09-01
Sarja:	Respiratory Research
Aiheet:	Chronic obstructive pulmonary disease Exacerbation FF/UMEC/VI Healthcare cost SITT
Linkit:	https://doi.org/10.1186/s12931-023-02523-1
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!